Can I Take Omega-3 (EPA/DHA) with MK-677 (Ibutamoren)?

Why This Combination Gets Flagged

MK-677 (ibutamoren) is a ghrelin-receptor agonist that stimulates growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion without requiring injection. It is not FDA-approved for any clinical indication, and most human data come from investigational trials in elderly or GH-deficient populations. Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are among the most widely used dietary supplements in the United States, taken by roughly 19 million adults according to NIH Office of Dietary Supplements data.

The interaction flag centers on two pharmacodynamic overlaps, not a drug-metabolizing enzyme conflict.

Triglyceride Metabolism

MK-677 consistently raises fasting triglycerides. In a 2-year randomized trial of ibutamoren 25 mg/day in healthy older adults (N=65), fasting triglycerides increased by approximately 10% from baseline compared to placebo [1]. A separate 12-month study in elderly subjects with hip fracture (N=161) confirmed this trend, with triglyceride elevations appearing within the first 6 weeks [2]. Growth hormone itself is lipolytic, but the resulting free fatty acid flux through the liver can increase hepatic VLDL-triglyceride output, a well-documented effect of GH-axis activation described in the Endocrine Society's 2011 GH guidelines.

Antiplatelet Activity

EPA and DHA reduce platelet aggregation through competitive inhibition of thromboxane A2 synthesis. MK-677 does not directly inhibit platelets, but elevated IGF-1 modulates endothelial nitric oxide production, which has downstream antithrombotic effects [3]. The practical bleeding risk from standard-dose omega-3 (1 to 3 g/day) is minimal, but the overlap is worth noting for anyone on concurrent anticoagulant or antiplatelet therapy.

Pharmacokinetics: No Enzyme-Level Conflict

MK-677 is primarily metabolized by CYP3A4 in the liver, with minor contributions from CYP2D6 [4]. Omega-3 fatty acids do not inhibit or induce CYP3A4, CYP2D6, or any other major cytochrome P450 isoform. A 2017 systematic review of omega-3 drug interactions published in the Journal of Clinical Lipidology confirmed that EPA and DHA have no clinically meaningful effect on CYP-mediated drug metabolism [5].

Absorption Considerations

Both MK-677 and omega-3 capsules are lipophilic. Taking them simultaneously on an empty stomach is unlikely to cause a pharmacokinetic problem, but co-ingestion of two fat-soluble compounds can increase GI motility in sensitive individuals. If nausea or bloating occurs, separating doses by 2 to 3 hours resolves the issue in most cases. MK-677 is typically taken at bedtime (to align GH pulsatility with natural sleep-associated secretion), while omega-3 supplements are commonly taken with a meal containing dietary fat to maximize absorption.

Protein Binding

MK-677 is highly protein-bound (greater than 90%). Omega-3 fatty acids do not displace protein-bound drugs at standard supplemental doses. This mechanism of interaction is not a concern here.

The Case for Combining Them

Omega-3 supplementation may actually counteract one of MK-677's metabolic downsides. The REDUCE-IT trial (N=8,179) demonstrated that icosapent ethyl 4 g/day reduced triglycerides by a median of 18.3% from baseline versus placebo in statin-treated patients with elevated triglycerides [6]. While REDUCE-IT used prescription-strength EPA, even standard over-the-counter omega-3 doses (2 to 3 g/day of combined EPA/DHA) lower triglycerides by 15 to 25% in hypertriglyceridemic individuals, according to a 2019 AHA advisory [7].

Triglyceride Math

A person starting MK-677 with a baseline triglyceride level of 150 mg/dL might see levels rise to 165 to 172 mg/dL based on the 10 to 15% increase observed in clinical trials [1][2]. Concurrent omega-3 supplementation at 2 g/day of EPA/DHA could offset some or all of that rise. This is not a guarantee, but the directional pharmacodynamics are favorable.

Anti-Inflammatory Overlap

GH-axis activation can increase C-reactive protein (CRP) and other inflammatory markers transiently. Omega-3 fatty acids, particularly EPA, reduce high-sensitivity CRP by 6 to 14% in meta-analytic data [8]. This secondary benefit does not constitute a reason to take both, but it does add context for clinicians evaluating the combination.

Monitoring Recommendations

Anyone using MK-677 (with or without omega-3) should have baseline and periodic lab work. The combination does not require unique monitoring beyond what each compound demands independently, but the shared triglyceride axis makes lipid tracking more important.

Baseline Labs (Before Starting MK-677)

• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Fasting glucose and HbA1c (MK-677 raises fasting glucose by 6 to 10 mg/dL on average [1])
• IGF-1 level
• Complete metabolic panel

Ongoing Monitoring Schedule

• Fasting lipid panel at 6 to 8 weeks, then every 12 weeks
• Fasting glucose at each lipid check
• IGF-1 at 8 weeks to confirm GH-axis response

When to Reassess

Triglycerides exceeding 300 mg/dL on the combination warrant either dose reduction of MK-677, escalation of omega-3 to prescription-strength EPA (icosapent ethyl 2 to 4 g/day), or discontinuation of MK-677. The Endocrine Society and the AHA both classify triglycerides above 500 mg/dL as a pancreatitis risk threshold requiring immediate intervention [7].

Dose-Separation and Practical Guidance

No mandatory dose-separation window exists for this combination. The following schedule reflects common practice among clinicians who manage patients using both compounds.

Suggested Timing

• Omega-3 (1 to 3 g/day EPA/DHA): with breakfast or dinner, alongside dietary fat
• MK-677 (10 to 25 mg/day): at bedtime, with or without food

This timing naturally creates 4 or more hours of separation and aligns MK-677 dosing with the nocturnal GH pulse. For individuals who prefer to take MK-677 with a meal (to reduce occasional nausea), evening dosing with dinner works, but omega-3 should then be moved to breakfast.

What to Watch For

• Mild GI bloating or loose stools when both are taken together (resolve by separating doses)
• Easy bruising or prolonged bleeding from minor cuts (relevant only if also taking aspirin, warfarin, or other anticoagulants)
• Peripheral edema, which is a GH-axis effect of MK-677 and is unrelated to omega-3

Special Populations

Patients on Anticoagulants or Antiplatelets

The additive antiplatelet effect of omega-3 and the indirect endothelial effects of IGF-1 elevation create a theoretical bleeding-risk increase. A 2018 Cochrane review of omega-3 supplementation found no statistically significant increase in major bleeding events at doses up to 4 g/day, even in patients on anticoagulants [9]. Still, clinicians should monitor INR more frequently (every 2 to 4 weeks initially) in patients on warfarin who start either compound.

Patients with Pre-Existing Hypertriglyceridemia

Starting MK-677 in a patient with triglycerides above 250 mg/dL creates a meaningful risk of pushing levels into the pancreatitis-risk zone. Omega-3 should be initiated first (or simultaneously), and a 6-week lipid check is non-negotiable in this population.

Patients with Insulin Resistance or Type 2 Diabetes

MK-677 worsens insulin sensitivity. A 2008 study by Nass et al. (N=65) showed fasting glucose rose by approximately 7 mg/dL and HOMA-IR increased significantly over 12 months [1]. Omega-3 fatty acids have a neutral to mildly beneficial effect on insulin sensitivity per a 2019 meta-analysis in Diabetes Care [10]. The combination does not worsen glycemic control beyond what MK-677 alone produces, but HbA1c monitoring at 12-week intervals is warranted.

What the Evidence Does Not Tell Us

Long-term safety data on MK-677 beyond 2 years do not exist. The compound never completed Phase III development for any indication, and the longest published trial is the 2-year Nass et al. Study [1]. No study has specifically evaluated the MK-677 plus omega-3 combination as a predefined endpoint. All guidance here is extrapolated from independent pharmacology of each compound and from general principles of GH-axis and lipid metabolism.

The Natural Medicines Comprehensive Database and the Mayo Clinic drug interaction checker do not list a specific MK-677/omega-3 interaction, which is consistent with the absence of a pharmacokinetic conflict. The pharmacodynamic overlaps described above are mechanistic inferences from published GH and omega-3 literature, not from dedicated interaction studies.

Clinician Decision Framework

For prescribers evaluating this combination in a patient who is already taking or requesting MK-677:

1. Check baseline triglycerides and fasting glucose before adding MK-677.
2. If triglycerides are above 150 mg/dL, start omega-3 (2 g/day EPA/DHA) concurrently or before MK-677 initiation.
3. Recheck fasting lipids at 6 to 8 weeks.
4. If triglycerides remain below 300 mg/dL and the patient tolerates the combination, continue with 12-week monitoring.
5. If triglycerides exceed 300 mg/dL, consider prescription-strength EPA (icosapent ethyl), MK-677 dose reduction to 10 mg/day, or discontinuation.

Fasting glucose at each monitoring visit guides decisions about concurrent metformin or other insulin-sensitizing interventions.